Extended Data Table 2.
Thirty-nine Cohort A Patient background and sample information.
| ID | Sex | Age (yr-old) | Ethnicity* | BMI (kg/m2) | COVID Risk factors† | C1‡ | DFSO at C1§ | Cmax∥ | DFSO at the first day of Cmax¶ | Deteriorated (Cmax > C1, yes=1, no=0) | Available data type# |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt003 | F | 49 | 5 | 35.0 | 0 | 1 | 17 | 1 | 0 | N, S, E, F1, F2, F3 | |
| Pt005 | F | 42 | 5 | 19.5 | 0 | 1 | 14 | 1 | 0 | E, F1, F2, F3 | |
| Pt019 | F | 56 | 3 | 30.1 | 3 | 2 | 5 | 3 | 11 | 1 | N, S, G, M, E, F1, F2, F3 |
| Pt022 | F | 56 | 3 | 30.3 | 3,4,5 | 1 | 7 | 3 | 14 | 1 | N, G, M, E, F1, F2, F3 |
| Pt032 | F | 69 | 5 | 23.9 | 0 | 1 | 7 | 1 | 0 | N, G, M, E, F1, F2, F3 | |
| Pt036 | F | 73 | 3 | 20.2 | 1,2,3 | 1 | 10 | 3 | 15 | 1 | N, S, G, M, E, F1, F2, F3 |
| Pt038 | F | 41 | 6 | 33.3 | 4 | 1 | 34 | 1 | 0 | N, S, G, M, E, F1, F2, F3 | |
| Pt044 | F | 26 | 5 | 33.5 | 0 | 1 | 20 | 1 | 0 | N, S, G, M, E, F1, F2, F3 | |
| Pt055 | F | 61 | 5 | 26.6 | 5 | 2 | 3 | 3 | 8 | 1 | N, S, G, M, E, F1, F2, F3 |
| Pt058 | F | 62 | 5 | 21.6 | 5 | 1 | 9 | 1 | 0 | S, G, M, E, F1, F2, F3 | |
| Pt070 | F | 53 | 5 | 27.1 | 0 | 2 | 12 | 1 | 0 | N, S, G, M, E, F1, F2, F3 | |
| Pt085 | F | 85 | 6 | 21.7 | 0 | 1 | 5 | 1 | 0 | G, M, E, F1, F2, F3 | |
| Pt086 | F | ≥ 90 | 5 | 18.5 | 1 | 2 | 3 | 1 | 0 | N, G, M, E, F1, F2, F3 | |
| Pt087 | F | 60 | 5 | 47.2 | 0 | 2 | 1 | 3 | 2 | 1 | N, G, M, E, F1, F2, F3 |
| Pt092 | F | 78 | 5 | 28.6 | 2,3 | 1 | 6 | 1 | 0 | N, S, G, M, E, F1, F2, F3 | |
| Pt105 | F | 86 | 5 | 27.1 | 3 | 1 | 15 | 1 | 0 | S, G, M, F1, F2, F3 | |
| Pt113 | F | 73 | 5 | 31.8 | 1,2,3 | 1 | 13 | 1 | 0 | N, G, M, E, F1, F2, F3 | |
| Pt119 | F | 84 | 3 | 33.6 | 3,4 | 1 | 12 | 1 | 0 | N, G, M, F1, F2, F3 | |
| Pt122 | F | 34 | 5 | 34.7 | 0 | 1 | 3 | 1 | 0 | G, M, E, F1, F2, F3 | |
| Pt123 | F | 52 | 5 | 24.1 | 4 | 1 | 17 | 1 | 0 | G, M, E, F1, F2, F3 | |
| Pt164 | F | 70 | 6 | 35.2 | 0 | 2 | 11 | 3 | 12 | 1 | S, G, M, F2, F3 |
| Pt170 | F | 55 | 6 | 25.2 | 0 | 1 | 27 | 1 | 0 | S, G, M, E, F1, F2, F3 | |
| Pt004 | M | 62 | 5 | 27.9 | 0 | 1 | 21 | 1 | 0 | N, S, G, M, E, F1, F2, F3 | |
| Pt007 | M | 44 | 5 | 25.6 | 3,4 | 1 | 10 | 1 | 0 | N, S, G, M, E, F1, F2, F3 | |
| Pt008 | M | 54 | 5 | 31.5 | 2,3,4 | 1 | 15 | 1 | 0 | E, F1, F2 | |
| Pt010 | M | 62 | 3 | 31.0 | 2,3 | 1 | 7 | 3 | 9 | 1 | N, S, G, M, E, F1, F2, F3 |
| Pt013 | M | 82 | 5 | 35.6 | 2,3 | 2 | 22 | 3 | 24 | 1 | N, G, M, E, F1, F2, F3 |
| Pt020 | M | 65 | 98 | 25.3 | 2,3 | 2 | 11 | 3 | 14 | 1 | N, S, E, F1, F2, F3 |
| Pt025 | M | 62 | 5 | 35.5 | 3 | 2 | 9 | 1 | 0 | N, S, G, M, E, F1, F2, F3 | |
| Pt027 | M | 70 | 5 | 24.6 | 1,4 | 1 | 3 | 1 | 0 | N, S, G, M, E, F3 | |
| Pt047 | M | 82 | 3 | 35.2 | 2,3 | 2 | 23 | 5 | 24 | 1 | N, S, G, M, E, F1, F2, F3 |
| Pt060 | M | ≥ 90 | 5 | 29.8 | 2,3 | 2 | 9 | 3 | 11 | 1 | N, G, M, E, F1, F2, F3 |
| Pt063 | M | 85 | 3 | 47.3 | 3 | 1 | 8 | 4 | 20 | 1 | G, M, E, F1, F2, F3 |
| Pt068 | M | 24 | 3 | 29.5 | 0 | 2 | 8 | 1 | 0 | G, M, F1, F2, F3 | |
| Pt074 | M | 35 | 3 | 28.0 | 0 | 1 | 4 | 1 | 0 | N, G, M, E, F1, F2, F3 | |
| Pt089 | M | 52 | 6 | 22.1 | 0 | 1 | 7 | 1 | 0 | N, S, G, M, E, F1, F2, F3 | |
| Pt095 | M | 42 | 6 | 19.3 | 0 | 1 | 7 | 1 | 0 | N, G, M, E, F1, F2, F3 | |
| Pt110 | M | 89 | 5 | 23.3 | 2,3 | 2 | 4 | 1 | 0 | N, G, M, E, F1, F2, F3 | |
| Pt116 | M | 53 | 5 | 26.4 | 4,5 | 1 | 6 | 1 | 0 | N, S, G, M, E, F1, F2, F3 |
Ethnicity: 1 - American Indian/ Alaskan native, 2- Asian, 3- Black/ African American, 4 - Native Hawaiian/ Pacific Islander, 5 - White, 6 - Hispanic, 9 - Multiple, 98 - Unknown/ unavailable.
COVID-related risk factors: 0 - No, 1 - cancer treatment within 1 yr, 2 - chronic heart disease, 3 - hypertension, 4 - chronic lung disease (asthma, COPD, ILD), 5-immunosuppression.
C1: Clinical score at the first sample collection date.
Days from symptom onset at the first sample collection.
Cmax: Maximum clinical score during the admission after the first time point sample collection.
Days from symptom onset at the first day Cmax was recorded in deteriorated patients.
Collected sample/data types at the first sample collection date.
N; Nasopharyngeal viral load, S; Saliva viral load, G; Plasma anti-S1-IgG, M; Plasma anti-S1-IgM, E; Plasma cytokine/chemokine ELISA, F1: flow cytometry PBMC cell composition staining, F2: flow cytometry T cell surface staining, F3: flow cytometry T cell intracellular staining.